![[Podcast] Behind the Breakthroughs: How Almac Powers Clinical Trial Success with Care](https://imgproxy.divecdn.com/5lAJkli_KcGt1FSsw4EaegjgP76IHREqYEWbhNBJOXw/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9CaW9QaGFybWFEaXZlXzEzNDZfeF83MjlfQXJ0d29yay5qcGc=.webp)
.jpg)
Novocure’s device for metastatic NSCLC treatment gains CE Mark
Novocure has obtained CE Mark approval for its Optune Lua device to treat adults with metastatic non-small cell lung cancer (NSCLC). The post Novocure’s device for metastatic NSCLC treatment gains CE Mark appeared first on Medical Device Network.
Novocure has obtained CE Mark approval for its Optune Lua device to treat adults with metastatic non-small cell lung cancer (NSCLC).
The post Novocure’s device for metastatic NSCLC treatment gains CE Mark appeared first on Medical Device Network.
